241 related articles for article (PubMed ID: 33838631)
1. AML-Associated Mutations in DNA Methyltransferase DNMT3A.
Khrabrova DA; Yakubovskaya MG; Gromova ES
Biochemistry (Mosc); 2021 Mar; 86(3):307-318. PubMed ID: 33838631
[TBL] [Abstract][Full Text] [Related]
2. Functional Analysis of DNMT3A DNA Methyltransferase Mutations Reported in Patients with Acute Myeloid Leukemia.
Khrabrova DA; Loiko AG; Tolkacheva AA; Cherepanova NA; Zvereva MI; Kirsanova OV; Gromova ES
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31861499
[TBL] [Abstract][Full Text] [Related]
3. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.
Russler-Germain DA; Spencer DH; Young MA; Lamprecht TL; Miller CA; Fulton R; Meyer MR; Erdmann-Gilmore P; Townsend RR; Wilson RK; Ley TJ
Cancer Cell; 2014 Apr; 25(4):442-54. PubMed ID: 24656771
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.
Sandoval JE; Huang YH; Muise A; Goodell MA; Reich NO
J Biol Chem; 2019 Mar; 294(13):4898-4910. PubMed ID: 30705090
[TBL] [Abstract][Full Text] [Related]
5. DNMT3A in Leukemia.
Brunetti L; Gundry MC; Goodell MA
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28003281
[TBL] [Abstract][Full Text] [Related]
6. Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.
Holz-Schietinger C; Matje DM; Reich NO
J Biol Chem; 2012 Sep; 287(37):30941-51. PubMed ID: 22722925
[TBL] [Abstract][Full Text] [Related]
7. Effect of
Tabatabaei T; Rezvany MR; Ghasemi B; Vafaei F; Zadeh MK; Zaker F; Salmaninejad A
Biomed Res Int; 2024; 2024():9625043. PubMed ID: 38807916
[TBL] [Abstract][Full Text] [Related]
8. The methyltransferase domain of DNMT1 is an essential domain in acute myeloid leukemia independent of DNMT3A mutation.
Bhogal B; Weir BA; Crescenzo R; Marien A; Kwon MC; Philippar U; Cowley GS
Commun Biol; 2022 Nov; 5(1):1174. PubMed ID: 36329185
[TBL] [Abstract][Full Text] [Related]
9. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
10. Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia.
Lin N; Fu W; Zhao C; Li B; Yan X; Li Y
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):270-277. PubMed ID: 29024628
[TBL] [Abstract][Full Text] [Related]
11. The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity.
Nguyen TV; Yao S; Wang Y; Rolfe A; Selvaraj A; Darman R; Ke J; Warmuth M; Smith PG; Larsen NA; Yu L; Zhu P; Fekkes P; Vaillancourt FH; Bolduc DM
J Biol Chem; 2019 Nov; 294(45):16966-16977. PubMed ID: 31582562
[TBL] [Abstract][Full Text] [Related]
12. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells.
Bera R; Chiu MC; Huang YJ; Liang DC; Lee YS; Shih LY
Neoplasia; 2018 Nov; 20(11):1106-1120. PubMed ID: 30245403
[TBL] [Abstract][Full Text] [Related]
13. Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia.
Jost E; Lin Q; Weidner CI; Wilop S; Hoffmann M; Walenda T; Schemionek M; Herrmann O; Zenke M; Brümmendorf TH; Koschmieder S; Wagner W
Leukemia; 2014 Jun; 28(6):1227-34. PubMed ID: 24280869
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia with DNMT3A mutations.
Li Y; Zhu B
Leuk Lymphoma; 2014 Sep; 55(9):2002-12. PubMed ID: 24283755
[TBL] [Abstract][Full Text] [Related]
15. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
Walter MJ; Ding L; Shen D; Shao J; Grillot M; McLellan M; Fulton R; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Kandoth C; Baty J; Westervelt P; DiPersio JF; Mardis ER; Wilson RK; Ley TJ; Graubert TA
Leukemia; 2011 Jul; 25(7):1153-8. PubMed ID: 21415852
[TBL] [Abstract][Full Text] [Related]
16. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
[TBL] [Abstract][Full Text] [Related]
17. [Functional role of DNMT3A mutation in acute myeloid leukemia].
Koya J; Kurokawa M
Rinsho Ketsueki; 2018; 59(5):602-610. PubMed ID: 29877252
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for impairment of DNA methylation by the DNMT3A R882H mutation.
Anteneh H; Fang J; Song J
Nat Commun; 2020 May; 11(1):2294. PubMed ID: 32385248
[TBL] [Abstract][Full Text] [Related]
19. DNMT3A mutations in acute myeloid leukemia.
Ley TJ; Ding L; Walter MJ; McLellan MD; Lamprecht T; Larson DE; Kandoth C; Payton JE; Baty J; Welch J; Harris CC; Lichti CF; Townsend RR; Fulton RS; Dooling DJ; Koboldt DC; Schmidt H; Zhang Q; Osborne JR; Lin L; O'Laughlin M; McMichael JF; Delehaunty KD; McGrath SD; Fulton LA; Magrini VJ; Vickery TL; Hundal J; Cook LL; Conyers JJ; Swift GW; Reed JP; Alldredge PA; Wylie T; Walker J; Kalicki J; Watson MA; Heath S; Shannon WD; Varghese N; Nagarajan R; Westervelt P; Tomasson MH; Link DC; Graubert TA; DiPersio JF; Mardis ER; Wilson RK
N Engl J Med; 2010 Dec; 363(25):2424-33. PubMed ID: 21067377
[TBL] [Abstract][Full Text] [Related]
20. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
